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Abstract
Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is
one of the most frequent events found in human tumours. In this study we set out to test the
hypothesis that loss of Rassf1a can co-operate with inactivation of the adenomatous polyposis coli
(Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (ApcMin/+) mouse model, as
mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal
cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of
the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including
regulation of the cell cycle, apoptosis, microtubule stability and most recently in the β-catenin
signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc+/Min mice
we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine
and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing
mice and decreased overall survival. Comparative genomic hybridization of adenomas from
Rassf1a−/−; Apc+/Min mice revealed no evidence of aneuploidy or gross chromosomal instability
(no difference to adenomas from Rassf1a+/+; Apc+/Min mice). Immunohistochemical analysis of
adenomas revealed increased nuclear β-catenin accumulation in adenomas from Rassf1a−/−;
Apc+/Min mice, compared to those from Rassf1a+/+; Apc+/Min mice, but no differences in
proliferation marker (Ki67) staining patterns. Collectively these data demonstrate co-operation
between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with
adenomas showing increased nuclear accumulation of β-catenin, supporting a mechanistic link via
loss of the known interaction of Rassf1 with β-TrCP that usually mediates degradation of β-
catenin.
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Introduction
The RASSF1A isoform of RASSF1 is frequently inactivated by epigenetic alterations in
human cancers, and RASSF1A has been reported to play a role in stabilising microtubules,
regulating cell cycle progression and activating pro-apoptotic pathways [reviewed in van der
Weyden & Adams, 2007]. There have been several reports of RASSF1A promoter
methylation with silencing of its expression in intestinal tumours with frequencies from
around 2% for adenomas to as high as 60% for malignant colorectal cancers [van Engeland
et al., 2002; Lee et al., 2004; Oliveira et al., 2005]. The most frequent early event in >80%
of sporadic colorectal cancers (CRCs) is point mutation or deletion of the adenomatous
polyposis coli (APC) gene, which is also mutated in the germline of patients with the
familial CRC syndrome, familial adenomatous polyposis (FAP) [Nishisho et al., 1991]. APC
inactivation leads directly to reduced β-catenin degradation with nuclear accumulation of β-
catenin producing aberrant Wnt pathway signalling as a key factor in adenoma initiation [Su
et al., 1992; Carothers et al., 2001]. Whether concomitant inactivation of RASSF1A and
APC is of functional significance in intestinal cancer is yet to be established. Interestingly it
has been proposed that the acquisition of activating mutations in K-ras, which has been
reported to occur in ~30-40% of colorectal tumours, is mutually exclusive to epigenetic
inactivation of RASSF1A [van Engeland et al., 2002]. Thus, tumours that have lost
RASSF1A and APC but retain wild-type K-ras may represent a different subclass of this
tumour.
Apc+/Min mice represent a valuable model of intestinal tumourigenesis, since sporadic loss
of heterozygosity (LOH) of the wild-type allele of Apc recapitulates the initiation of
adenomagenesis observed in humans. Similarly, Rassf1a null mice show an increased
incidence of spontaneous and induced tumorigenesis [van der Weyden et al., 2005;
Tommasi et al., 2005]. Importantly, isoform-specific Rassf1a null mice irradiated with 3.5
Gy of ionizing radiation to stimulate DNA damage, show an increased susceptibility to
tumours associated with the intestinal tract (adenomas and adenocarcinomas) [van der
Weyden et al., 2005]. Thus, using these models, we set out to test the hypothesis that loss of
Rassf1a can co-operate with inactivation of Apc to accelerate intestinal tumourigenesis in
vivo. Additionally, our aim was to use this model to address the possible mechanism of any
such co-operation between these genes.
Rassf1a-deficient Apc+/Min mice show increased intestinal adenoma
formation
Isoform-specific Rassf1a null mice (on a mixed C57BL6/J–129S5 background) [van der
Weyden et al., 2005] and Apc+/Min mice (on a C57BL6/J background) [Su et al., 2002] were
interbred to generate Rassf1a+/+, Rassf1a+/− and Rassf1a−/− mice on an Apc+/Min
background. Rassf1a mice were born at expected Mendelian frequencies on the Apc+/Min
background (data not shown). Littermates of each genotype were used for all studies and
mice were housed in a pathogen-free barrier environment. Rassf1a [van der Weyden et al.,
2005] and Apc+/Min [Su et al., 1992] genotyping was carried out by PCR according to
previously published procedures. Since Apc+/Min mice typically develop multiple intestinal
adenomas by 16 weeks of age [Su et al., 1992; Luongo et al., 1994; Moser et al., 1990], we
initially set out to determine the relative multiplicity of adenoma formation at the 16 week
timepoint according to the three Rassf1a backgrounds. At 16 weeks, wild-type, Rassf1a
heterozygotes and Rassf1a null homozygotes on a Min background were sacrificed and their
intestines removed and examined under the dissecting microscope for the presence of visible
adenomatous polyps. As shown in Figure 1a, Rassf1a−/−; Apc+/Min mice showed
significantly more adenomas (24.3 ± 1.6, n=30) than Rassf1a+/−; Apc+/Min mice (14.0 ± 1.0,
n=21) or Rassf1a+/+; Apc+/Min mice (15.6 ± 2.1, n=11; p=0.005 by unpaired Students t-test
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(two-tailed) for Rassf1a+/+ vs. Rassf1a−/−; data shown as mean ± SEM). This observation
was confirmed when the intestines and colon were individually prepared as Swiss-rolls,
histologically processed and examined by light microscopy for adenomas (Figure 1b). There
was no significant difference in adenoma number between Rassf1a+/+; Apc+/Min and
Rassf1A+/−; Apc+/Min mice (p=0.465). The vast majority of the adenomas observed were in
the small intestine and were hemispherical in shape forming sessile polyps on the surface of
the mucosa, although the occasional pedunculated colonic polyp was observed. Small
intestinal polyps varied in size from 0.5 and 2 mm in diameter, whereas large intestinal
polyps varied between 1 and 3 mm, and there was no significant difference in polyp size
between Rassf1a+/+; Apc+/Min and Rassf1A−/−; Apc+/Min mice. Collectively these data show
that inactivation of Rassf1a and Apc co-operate to increase the number of intestinal
adenomas formed.
Rassf1a-deficient Apc+/Min mice show decreased survival
Given that Rassf1a−/−; Apc+/Min mice develop more adenomas than their littermates by 16
weeks of age, we next set out to determine whether there were any effects on progression to
intestinal adenocarcinoma. We placed cohorts of Rassf1a+/+; ApcMin/+, Rassf1a+/−;
Apc+/Min and Rassf1a−/−; Apc+/Min mice on tumour watch until they became moribund, at
which point the mice were humanely sacrificed and a full necropsy performed, with all
organs being processed for histopathological analysis. As shown in Figure 2a, Rassf1a−/−;
Apc+/Min mice showed a decreased survival (27.5 weeks median survival), compared to
Rassf1a+/−; Apc+/Min mice (38.5 weeks median survival) and Rassf1a+/+; Apc+/Min mice
(33.5 weeks median survival; p<0.0001 by Logrank test for Rassf1a+/+ vs. Rassf1a−/−).
Although there was no difference in the numbers of mice developing leukaemia or
lymphoma (3/33 [9%] and 5/52 [9%] for Rassf1a+/+ and Rassf1a−/− mice, respectively),
histopathological analysis was carried out on the small intestines and colons to look for a
difference in the numbers of mice which developed (i) adenomas, (ii) adenomas of a specific
pathological grade of dysplasia, or (iii) adenocarcinomas (Figure 2b). There was a greater
trend towards moderate to high grade dysplasia (combined grades 2 & 3, relative to grade 1
mild dysplasia) for Rassf1a−/−; Apc+/Min adenomas compared to Rassf1a+/+; Apc+/Min
adenomas (trend approaching significance with p=0.055 by Fisher’s Exact test).
Interestingly, the age at death for intestinal adenocarcinoma-bearing mice was significantly
lower in Rassf1a−/−; Apc+/Min mice (228.8 ± 18.4 days, n=9) compared with Rassf1a+/+;
Apc+/Min mice (292.0 ± 26.4 days, n=5; p=0.034 by unpaired t-test, one-tailed), as shown in
Figure 2c. Such earlier death may reflect greater numbers of adenomas in this cohort,
increasing the likelihood of one of them progressing to malignancy at an earlier time. Thus,
while loss of Rassf1a increases the formation and/or early growth of intestinal adenomas on
the Apc+/Min background, it appears not to contribute significantly to the progression of
these premalignant lesions to adenocarcinomas, consistent with RASSF1A inactivation
being an early event in tumorigenesis [reviewed in van der Weyden & Adams, 2007].
Rassf1a-deficient Apc+/Min mice develop intestinal adenomas that display
increased nuclear β-catenin accumulation
APC, in association with the serine-threonine glycogen synthase kinase, GSK-3β, down-
regulates intracellular levels of β-catenin and the oncogenic effects of APC deficiency are in
large part attributable to excess levels of β-catenin [Su et al., 1992]. Loss of the wild-type
Apc allele in Apc+/Min murine adenomas results in inactivation of both Apc alleles with
increased intracellular accumulation of β-catenin [Carothers et al., 2001], and it was recently
found that over-expression of RASSF1C, or silencing of RASSF1A, also resulted in
increased nuclear β-catenin accumulation due to an inhibition of βTrCP-mediated β-catenin
degradation [Estrabaud et al., 2007]. Importantly, immunohistochemical analysis of β-
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catenin expression in Rassf1a−/−; Apc+/Min murine adenomas at 16 weeks of age showed
increased nuclear accumulation of β-catenin in terms of both a greater number of cells
showing this pattern and an increased intensity of nuclear β-catenin staining, compared to
histologically matched Rassf1a+/+; Apc+/Min murine adenomas (Figure 3a, b). Adenomas
collected at the time of death from these two groups of mice on tumour watch did not show
such clear differences in the levels of β-catenin expression (Figure 3c, d). Interestingly, a gut
tumour (large jejunal adenoma with severe dysplasia) arising from an irradiated Rassf1a−/−
mouse [van der Weyden et al., 2005] also showed strong nuclear β-catenin staining (Figures
3e, f), suggesting that concomitant loss of Rassf1a and activation of β-catenin had occurred.
The physical interaction of RASSF1C with β-TrCP via the SS18GYXS19 motif found in
RASSF1C has been proposed to result in the inhibition of β-TrCP-mediated degradation of
β-catenin, and this may result in tumour promotion [Estrabaud et al., 2007]. Intriguingly,
inhibition of RASSF1A or overexpression of RASSF1C was shown to inhibit β-TrCP in
transiently transfected HeLa cells. We set out to investigate this mechanism further by
examining expression of β-catenin in the normal intestines of our Rassf1a null mice which
have isoform-specific deletion of Rassf1a but express wild-type levels of Rassf1c mRNA
[van der Weyden et al., 2005]. We saw no difference in the levels of expression or
subcellular localization of β-catenin in the normal epithelium of the small and large
intestines of Rassf1a null mice when compared to wild-type controls, either at 2 days of age
(Figures 3g, h), 12 weeks of age (Figures 3i, j) or 17 weeks of age (data not shown). As
Rassf1a null mice become viable healthy young adults (prior to tumour susceptibility later
on), this strongly suggests that loss of Rassf1a on its own does not result in a sufficiently
elevated constitutive activation of β-catenin, since activated β-catenin signalling either by
overexpression of β-catenin itself [van Amerongen and Berns, 2006] or by loss of Apc
results in embryonic lethality [Su et al., 2002].
Thus, it seems likely that increased accumulation of β-catenin due to interference of the
interaction between β-TrCP and RASSF1C, resulting from loss of RASSF1A, may only
become relevant in the setting of tumour formation where β-catenin is already partly
activated, such as via inactivation by mutation and/or loss of Apc. A similar mechanism of
co-operative activation of β-catenin has been demonstrated by inactivation of the secreted
frizzled related protein (SFRP) gene together with APC inactivation in human colon cancer
[Taketo, 2004]. Thus, Rassf1a inactivation during intestinal tumour formation may further
deregulate Wnt pathway signalling leading to increased accumulation of β-catenin, which
can further contribute to the oncogenic effects of aberrant Wnt/β-catenin signalling [Reya &
Clevers, 2005].
Rassf1a-status does not appear to affect the pattern of proliferation marker
staining in adenomas or normal intestinal epithelium from Apc+/Min mice
Given that Rassf1a−/−; Apc+/Min mice show increased adenoma formation at 16 weeks
(Figure 1), and RASSF1A has been reported to play an important role in regulating cell
cycle/mitotic progression [reviewed in van der Weyden & Adams, 2007], we looked to see
whether there was an increase in the compartment of cells within the intestine that was
cycling/proliferating, as assessed by immunohistochemistry with Ki-67 antibody (the Ki-67
nuclear antigen is present throughout most of the cell cycle, and Ki-67
immunohistochemistry provides a reliable means of rapidly evaluating the growth fraction
of normal and neoplastic cell populations [Gerdes et al., 1984]). However, we observed no
difference in the number or distribution of Ki-67 positive cells in either the normal intestinal
epithelium or the adenomas of Rassf1a−/−; Apc+/Min mice compared to Rassf1a+/+; Apc+/Min
mice controls (Figure 3k-n), suggesting that deregulation of the cell cycle detectable by this
method is unlikely to be the mechanism of action by which Rassf1a inactivation enhances
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adenoma formation in Min mice. Similarly, no differences were found in the prevalence of
apoptotic figures identified in haematoxylin-eosin stained sections of either normal intestinal
epithelium or adenomas from these two groups of mice (data not shown).
No evidence of aneuploidy or gross genomic instability in intestinal
adenomas from Rassf1a−/−; Apc+/Min mice
The RASSF1A gene has been shown to interact with the pro-apoptotic kinase MST1 and to
complex with MST2 and WW45, homologues of Sav and LATS1 respectively [Guo et al.,
2007]. Dysregulation of this complex by inactivation of Rassf1a has been proposed to result
in cytokinesis failure and delayed mitosis [Guo et al., 2007], and failed or stalled exits from
mitosis may promote genomic instability. Furthermore, transient knockdown of RASSF1A
in foreskin fibroblasts has been shown to cause mitotic abnormalities including multiple
centrosomes and lagging chromosomes that were postulated to contribute to chromosomal
instability [Song et al., 2004]. However, although tumour-prone, Rassf1a null mice do not
show any evidence of gross genomic instability [van der Weyden et al., 2005]. Thus, to
determine if co-operation between inactivated RASSF1A and APC could promote genomic
instability within tumours, we subjected adenomas from Rassf1a−/−; Apc+/Min and
Rassf1a+/+; Apc+/Min mice to comparative genomic hybridization to gain a genome-wide
profile of genomic gains and losses. The statistically significant chromosomal alterations
found in these Rassf1A, Apc+/Min adenomas are listed in Supplemental Table 1. Two
commonly recurring chromosomal alterations, namely a ~3.5 Mb amplification on
chromosome 14 (present in 5/12 samples) and a 282 kb deletion on chromosome 17 (present
in 6/12 samples) represent previously documented copy number variants (CNV) between the
C57BL/6J and 129Sv mouse strains [Adams et al., 2005; Graubert et al., 2007]. Interestingly
only one Rassf1A, Apc+/Min adenoma (number 11) showed a ~4 Mb deletion on
chromosome 18 encompassing the murine Apc gene. However, there was no evidence of
aneuploidy (i.e., loss or gains of whole chromosomes), suggesting that a defect in
microtubule stability is not a major determinant of the accelerated intestinal tumourigenesis
seen in the Rassf1a−/−; Apc+/Min mice. Furthermore, there was no difference in average copy
number alterations in adenomas from these two groups (9.3 ± 1.5 gains or losses per
adenoma for Rassf1a+/+; Apc+/Min mice and 7.1 ± 5.3 gains or losses per adenoma for
Rassf1a−/−; Apc+/Min mice). These levels of copy number alterations are consistent with the
frequency observed for adenomas from the Apc+/1638N mouse model [Alberici et al., 2007].
In this study we set out to test the hypothesis that inactivation of both Rassf1a and Apc
could co-operate in the formation of intestinal tumours in vivo. We observed increased
adenoma formation in Rassf1a−/−; Apc+/Min mice at 16 weeks of age, decreased survival in
tumour watch animals and a decreased latency of adenocarcinoma formation, suggesting
that inactivation of both Rassf1a and Apc, which is frequently observed in tumours of the
human intestinal tract, is an important mechanism of tumour initiation and early growth of
intestinal adenomas. By immunohistochemical analysis of the adenomas from Rassf1a−/−;
Apc+/Min compared to those from Rassf1a+/+; Apc+/Min mice, we were able to demonstrate
enhanced nuclear accumulation of β-catenin, indicative of increased β-catenin signalling.
This may represent an important mechanistic link by which inactivation of Apc and Rassf1a
co-operate in tumour formation, as both Apc (via GSK3β) and Rassf1 (via β-TrCP) usually
bring about β-catenin degradation. Thus, abnormality of both of these β-catenin degradation
pathways may combine to produce higher levels of nuclear β-catenin in tumour cells than
occur with either alone, conferring a co-operative oncogenic effect of inactivation of both
Rassf1a and Apc.
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Figure 1.
Rassf1a-deficient Apc+/Min mice show increased intestinal adenoma formation. At 16 weeks
of age intestines were collected from Rassf1a+/+ (n=11), Rassf1a+/− (n=21) and Rassf1a−/−
(n=30) mice on an Apc+/Min background. (a) The intestines were opened and analysed for
number and location of adenomas (polyps) with the help of a dissecting microscope. The bar
indicates mean value for each genotype. (b) The intestines were then prepared as Swiss-rolls
and histologically analysed following haematoxylin-eosin staining (circles outline the
adenomas). All sections shown are representative. Magnification: x25.
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Figure 2.
Rassf1a-deficient Apc+/Min mice show decreased survival. (a) Kaplan-Meier plots show the
percentages of survival of Rassf1a+/+, Rassf1a+/− and Rassf1a−/− mice on an Apc+/Min
background. (b) When the mice became moribund, their intestines were collected and
prepared as Swiss-rolls for histological analysis following haematoxylin-eosin staining. The
processed intestines from Rassf1a+/+; Apc+/Min (n=33) and Rassf1a−/−; Apc+/Min (n=52)
were analysed for the presence of adenomas (grouped into grades 1-3 based on their number
and degree of dysplasia) and adenocarcinomas. (c) The age at death for mice bearing
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intestinal adenocarcinomas was compared between Rassf1a+/+; Apc+/Min (n=6) and
Rassf1a−/−; Apc+/Min (n=9) mice. The bar indicates mean value for each genotype.
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Figure 3.
β-catenin and Ki-67 staining in intestines. Intestines at 16 weeks showed β-catenin staining
in the adenomas of Rassf1a+/+; Apc+/Min mice (a) with increased nuclear accumulation in
adenomas of Rassf1a−/−; Apc+/Min mice (b). Adenomas collected at the time of death from
Rassf1a+/+; Apc+/Min (c) and Rassf1a−/−; Apc+/Min (d) mice on tumour watch did not show
such clear differences in nuclear β-catenin expression. (e, f) Strong nuclear β-catenin
staining was observed in an intestinal adenoma arising from an irradiated Rassf1a−/− mouse.
In contrast, no difference in the level of expression or subcellular localization of β-catenin
was found in intestines from Rassf1a+/+ (g, i) or Rassf1A−/− (h, j) mice at 2 days or 12
weeks (respectively). Intestines at 16 weeks showed no difference in the number or
distribution of Ki-67 positive cells in either the normal epithelium (k, l) or adenomas (m, n)
of Rassf1a+/+; Apc+/Min and Rassf1a−/−; Apc+/Min mice, respectively.
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Immunohistochemistry was performed using anti-β-catenin (1:500 dilution; Sigma-Aldrich,
Dorset, UK) or anti-Ki-67 (1:50 dilution; sp6 clone, DCS Diagnostics, Hamburg, Germany).
Immunohistochemical signal was detected by secondary biotinylated donkey anti-rabbit
antibody (1:500 dilution; Stratech Scientific, Suffolk, UK), followed by Vector ABC tertiary
kit (Vector Laboratories, Burlingame, CA) according to the manufacturer’s instructions. All
immunohistochemistry was performed on a BondMax machine (Vision Biosystems,
Newcastle, UK) according to the manufacturer’s instructions and involved antigen retrieval
by BondMax Epitope retrieval solution heated on the machine for 20 minutes. All sections
shown are representative. Magnification: x400 (a-f) and x200 (g-n).
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